Hologic Inc HOLX and Grifols, S.A. GRFS announced Monday that they won FDA approval for the use of the Procleix Zika virus blood screening assay.
U.S. blood centers will use Procleix to screen blood donations in the Southern US and other areas potentially affected by the virus. The American Red Cross has partnered with Hologic and Grifols to perform the Procleix Zika Virus assay investigational study.
Hologic and Grifols shares closed Monday at $34.14 and $15.58, respectively, both up about 1 percent from Friday's close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.